AzTrials
AzTrials

RehabilitationNCT04872153

Exergames in In-patient Rehabilitation

A study testing Dividat Senso Exergames in people with Rehabilitation and Cardiovascular Diseases, run by Eling DeBruin at 2 sites in Switzerland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This pilot trial aims to evaluate the feasibility and effectiveness of a technology-based intervention for cognitive-motor training in rehabilitation clinics with geriatric, neurological and cardiac patients. Read more about this study

Who is it for?
Ages 50 years and older
What is being tested?
Dividat Senso Exergames
Could I receive a placebo?
No, everyone receives an active treatment
How many people
84 participants
Where
2 sitesSwitzerland
Study dates
13 Jan 2021to 30 Jan 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with prescription for rehabilitation*
  • ≥ 50 years old
  • Able to score ≥ 20 at the Mini Mental State Examination (MMSE)
  • Able to provide a signed informed consent
  • Physically able to stand for at least 3min without external support (self-report)

Who cannot join

  • Mobility or cognitive limitations or comorbidities which impair the ability to use the training games and overall system
  • Conservatively treated osteoporotic fractures
  • Previous or current major psychiatric illness (e.g. schizophrenia, bipolar disorder, recurrent major depression episodes)
  • History of drugs or alcohol abuse
  • Terminal illness
  • Severe sensory impairments (mainly visual, auditory, color blindness)
  • Insufficient knowledge of German to understand the instructions/games
  • *In the rehabilitation clinics involved as study centres, mainly persons suffering from cardiovascular diseases (clinic Seewis), persons suffering from neurological diseases (esp. Parkinson's Disease according to the United Kingdom Brain Bank criteria) (clinic Zihlschlacht) and geriatric patients (clinic Dussnang) will be included in this study.

Trial locations and contacts

2 sites in 1 country.

Switzerland2 sites
  • Rehaklinik Dussnang

    Dussnang, Thurgau, 8374

  • Rehaklinik Zihlschlacht

    Zihlschlacht-Sitterdorf, Thurgau, 8588

Other trials in Switzerland

About this study

Official title: Feasibility of Technology-based Cognitive-motor Training in Rehabilitation: A Pilot-trial

This pilot trial aims to evaluate the feasibility and effectiveness of a technology-based intervention for cognitive-motor training in rehabilitation clinics with geriatric, neurological and cardiac patients.

The primary objective of this pilot study is to evaluate the feasibility of exergame-based cognitive-motor training in in-patient rehabilitation settings.

The secondary objective of this pilot trial is to evaluate the effectiveness of an expanded rehabilitation treatment (combining exergame training with conventional care) on physical and cognitive functioning in different patient groups.

Read the detailed description

This study is a pilot trial with two arms: an intervention group where the conventional treatment during the stay in the in-patient rehabilitation clinic is extended with a technology-based cognitive-motor intervention and a control group following just the conventional treatment. Participants will be randomly allocated to one of the two groups. The selected methods to evaluate the primary and secondary endpoints include quantitative and qualitative measures. This national study will be conducted in Switzerland in a multicentre setup; three rehabilitation clinics are involved as study centres.

The study will include at least 40 patients in each of the rehabilitation clinics involved as study centres (20 patients in the intervention group, 20 patients in the control group), resulting in a total sample size of 120 patients. At clinic entry, patients potentially fulfilling all inclusion criteria will be informed in oral and written about the study and asked if they wish to participate. All interested participants will then be screened for eligibility. The included participants will then undergo a baseline assessment battery and will be subsequently randomly allocated to the intervention or the control group using a block randomization.

Screening as well as baseline measurements (T1-measurements) are conducted within the first two days upon entry at the rehabilitation clinic. T1-measurements will last around 60-70 minutes. One day after T1- measurements, the intervention will begin (for patients in the intervention group). The intervention period will be equal to the length of the stay in the rehabilitation clinic (between 2-3 weeks, according to each cantonal/regional regulations and insurance coverage) and will include short daily training sessions using the Dividat Senso (5x/week à 10-15min), resulting in 10 to 15 training sessions in total. The training sessions will be supervised by a qualified study investigator (carefully observing patients while training and also preventing/aiding in case of adverse events). At the last two days before discharge from the clinic, post-measurements (T2-measurements) will be performed with all (intervention \& control) study participants. T2-measurements last around 70-80 minutes.

Intervention group:

The patients allocated to the intervention group will conduct simultaneously combined cognitive- motor training on a technological device providing exergames, the Dividat Senso. Both, the hardware (Dividat Senso) and the software (exergames) are specifically developed considering the needs and requirements of older adults but also clinicians/therapists.

The Dividat Senso is a platform for the dynamic recording of steps, weight shifts and other body movements producing forces. The platform includes 20 sensors (strain gauges), 5 vibration motors and an light-emitting diode (LED) control. It is certified as a medical device class 1 and used by clinics, hospitals and nursing and care homes in 15 countries worldwide. It is connected to a small computer (running the software) and a large screen.

The Dividat exergames specifically target all cognitive functions relevant for the successful mastering of activities of daily living such as executive and attentional functions and physical functions such as balance and coordination. The games are played by conducting body movements, mainly steps in four directions (front, right, left, back) but also body weight shifting.

The Dividat software is a web-based environment that includes data backing (Dividata), an administrative interface (Dividat Manager) and an intelligent, adaptable training environment with the exergames for motor-cognitive training (Dividat Play). In the Dividat Manager, participants can be registered as users and their training program can be managed. The training software (Dividat Play) contains an algorithm for automatic, real-time adaptation of the difficulty of a training game to the skills of a user. Moreover, the training applied in this study is progressive in the course of the intervention period; patients start with the easier games in the first week, progressing to more difficult games in the second week and so on. Therapists and study investigators have the opportunity to individually adapt the training plan to meet each patient's functional capacity in the Dividat Manager. Thus, personalized training and optimal challenge for each patient are ensured.

The intervention period in the rehabilitation setting will be equal to the length of the stay in the rehabilitation clinic (between 2-3 weeks, according to each cantonal/regional regulations and insurance coverage) and will include short daily training sessions using the Senso (5x/week à 10- 15min), resulting in 10 to 15 training sessions in total.

Each session contains various combinations of the Dividat exergames (each of the games lasts around 2-3min).

Control group:

The patients of the control group follow the standard rehabilitation procedure including per week: 3x 30min physiotherapy, 8x 30min group therapy, 3x 45min group therapy (group therapy includes body- focused therapy, mindfulness therapy, respiratory therapy, gymnastics, hiking etc.).

Being tested
Dividat Senso Exergames
Keywords
exergame, motor-cognitive training, feasibility, rehabilitation
Medical subject headings
Cardiovascular Diseases, Parkinson Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Dividat Senso ExergamesBehavioural

    The intervention period in the rehabilitation setting will be equal to the length of the stay in the rehabilitation clinic (between 2-3 weeks, according to each cantonal/regional regulations and insurance coverage) and will include short daily training sessions using the Senso (5x/week à 10- 15min), resulting in 15 to 20 training sessions in total.

    Each session contains various combinations of the Dividat exergames (each of the games lasts around 2-3min).

Study groups in NCT04872153
Study groupRoleWhat they receive
Intervention GroupExperimentalThe patients allocated to the intervention group will conduct simultaneously combined cognitive-motor training in form of exergames using the Dividat Senso in addition to the standard rehabilitation treatment plan. Both the Dividat Senso and the training games are specifically developed considering the needs and requirements of older adults but also clinicians/therapists.
Receives: Behavioral: Dividat Senso Exergames
Control GroupNo interventionThe patients of the control group follow the standard rehabilitation treatment plan including: 3x 30min physiotherapy, 8x 30min group therapy, 3x 45min group therapy (group therapy includes body- focused therapy, mindfulness therapy, respiratory therapy, gymnastics, hiking etc.)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Adverse Events

    Related and un-related adverse events during the pre-post assessments as well as during each training session will be registered

    Measured: Adverse events are assessed during the data collection period, an average of 3 to 4 weeks.

  2. Attrition rate

    Number of participants lost during the trial will be recorded (drop-outs in both groups)

    Measured: The attrition rate is assessed during the data collection period, an average of 3-4 weeks.

  3. Adherence rate

    Percentage of the number of attended training sessions in relation to the number of planned training sessions

    Measured: The adherence rate is assessed for all training sessions during the intervention period, an average of 3-4 weeks.

  4. System Usability Scale (SUS)

    Participants of the intervention group will receive a survey form at the end of the intervention period regarding usability of the device used for the delivery of the exergame training (Dividat Senso)

    Measured: The SUS is completed at the post-measurement by the intervention group. The survey lasts 2 minutes.

  5. Nasa Task Load Index (NASA-TLX)

    The NASA-TLX is a self-report, multidimensional assessment tool that rates perceived workload in order to assess a task, a system, or other aspects of performance (in this case the DIVIDAT exergames). It contains five subscales: Mental Demand, Physical Demand, Temporal Demand, Performance, Effort and Frustration. A score from 1-100 is calculated based by averaging all answers to all questions.

    Measured: The NASA-TLX is assessed after each training sessions during the intervention period. The survey lasts 1-2 minutes.

  6. User Experience

    A questionnaire with (self-developed) questions regarding perceived enjoyment during training, perceived positive effects, intention to use after study's end etc. will be filled out by the intervention group

    Measured: The questionnaire is completed at the post-measurement by the intervention group. The survey lasts 2 minutes.

  7. Training motivation

    Average training motivation based on motivation question in each session (Scale 1-5) answered by patients.

    Measured: The question is assessed before each training session during the intervention period, an average of 3-4 weeks..

Secondary outcomes (8)
  1. Changes in psychomotor speed

    The Reaction Time Test (6-RTT) conducted on the Dividat Senso measures psychomotor speed in terms of reaction to visual stimuli using the lower extremities in 6 directions (front right, front left, right, left, back right \& back left).

    Measured: Assessment takes place at pre- and post-measurement within the two days after entry respectively before discharge. The 6-RTT lasts 5 minutes.

  2. Changes in mental flexibility

    To assess mental flexibility (a part of executive functions), the Trail Making Test (TMT) is used pre- and post-intervention. This paper-pencil-test is resulting in a time value in seconds. Less time needed to conducted the test is related to better performance.

    Measured: Assessment takes place at pre- and post-measurement within the two days after entry respectively before discharge. The TMT lasts ca. 10 minutes.

  3. Changes in inhibitory control

    To assess interference control (a part of executive functions), the Color-Word Interference Test is used pre- and post-intervention. The result is a time value measured in seconds, furthermore, errors are counted. Less time and less errors is related to better performance.

    Measured: Assessment takes place at pre- and post-measurement within the two days after entry respectively before discharge. The test lasts 10 minutes.

  4. Changes in selective attention

    The Go/No-Go Test conducted on the Dividat Senso measures selective attention. Participants fixate on a small grey dot in the middle of the screen. Crosses (+) and Xs (x) appear on the right and left side of the grey dot in randomised order. The task is to ignore the + and just conduct a step as quickly as possible as soon as in the direction that an x appears.

    Measured: Assessment takes place at pre- and post-measurement within the two days after entry respectively before discharge. The Go/No-Go lasts 5 minutes.

  5. Changes in functional mobility

    The Timed Up and Go (TUG) test is conducted. At the start signal participants must stand up from a chair, walk three meters at a comfortable walking speed, come back and sit down on the chair again. Time to complete the task in seconds is recorded. The use of walking aids is noted.

    Measured: Assessment takes place at pre- and post-measurement within the two days after entry respectively before discharge. The TUG lasts 2 minutes.

  6. Changes in physical performance

    To assess physical performance the Short Physical Performance Battery (SPPB) is used resulting in a total score of 12 points with a minimum score of 0 and a maximum score of 4 for each sub-test. The SPPB consist of 3 sub-tests including a balance test (e.g. tandem stance, semi-tandem stance, single leg stance), 4-meter gait test, and 5-chair rises test. A higher score means a better balance performance.

    Measured: Assessment takes place at pre- and post-measurement within the two days after entry respectively before discharge. The SPPB lasts 5 minutes.

  7. Changes in Single-Task Walking

    Participants have to walk a 10m distance at their preferred speed and their maximal speed while still feeling safe.

    Measured: Assessment takes place at pre- and post-measurement within the two days after entry respectively before discharge. The Single-Task Walk lasts 3 minutes.

  8. Changes in Dual-Task Walking

    Participants have to walk a 10m distance at their perferred speed while calculating serial sevens backwards.

    Measured: Assessment takes place at pre- and post-measurement within the two days after entry respectively before discharge. The Dual-Task Walk lasts 3 minutes.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 May 2021
  2. Study start13 Jan 2021
  3. Primary completion30 Jan 2021
  4. Study completion30 Jan 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
84 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04872153
Sponsor's protocol ID
BASEC Nr. 2020-02388
Status last verified
Dec 2022
First submitted
29 Mar 2021
Last updated
9 Dec 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Ernst M, Folkerts AK, Gollan R, Lieker E, Caro-Valenzuela J, Adams A, Cryns N, Monsef I, Dresen A, Roheger M, Eggers C, Skoetz N, Kalbe E. Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2024 Apr 8;4(4):CD013856. doi: 10.1002/14651858.CD013856.pub3.

    PubMed 38588457
  • Jaggi S, Wachter A, Adcock M, de Bruin ED, Moller JC, Marks D, Schweinfurther R, Giannouli E. Feasibility and effects of cognitive-motor exergames on fall risk factors in typical and atypical Parkinson's inpatients: a randomized controlled pilot study. Eur J Med Res. 2023 Jan 16;28(1):30. doi: 10.1186/s40001-022-00963-x.

    PubMed 36647177
  • Ernst M, Folkerts AK, Gollan R, Lieker E, Caro-Valenzuela J, Adams A, Cryns N, Monsef I, Dresen A, Roheger M, Eggers C, Skoetz N, Kalbe E. Physical exercise for people with Parkinson's disease: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023 Jan 5;1(1):CD013856. doi: 10.1002/14651858.CD013856.pub2.

    PubMed 36602886

Questions about this trial

What is this clinical trial studying?

A study testing Dividat Senso Exergames in people with Rehabilitation and Cardiovascular Diseases, run by Eling DeBruin at 2 sites in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Adverse Events (time frame: Adverse events are assessed during the data collection period, an average of 3 to 4 weeks.). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04872153, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Dec 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in